NEW YORK (GenomeWeb News) – Qiagen made three acquisitions in April and May for up to $181.7 million, it disclosed in a document filed yesterday with the US Securities and Exchange Commission.

In its Form 10-Q Qiagen said that the acquisitions included the remaining 60 percent of Scandinavian Gene Synthesis that it didn't already own, and AmniSure International. Qiagen did not provide details on its third acquisition.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.